V enous thromboembolism (VTE), comprising both deep vein thrombosis (DVT) and pulmonary embolism (PE), affects >600 000 persons annually in the United States. 1 Nearly two thirds of VTEs occur in the setting of hospitalization, and they account for ≈300 000 deaths annually. 1, 2 In addition to the substantial morbidity and mortality, VTE is also a financial burden to society with estimated annual costs of $4.9 to $7.5 billion for DVT and $8.5 to $19.8 billion for PE in the United States. 3 Antithrombotic therapy has been shown reduce recurrent VTE and associated mortality and is the standard of care for the acute treatment of VTE. 4, 5 Historically, the standard regimen has been the initiation of a parenteral anticoagulant, such as heparin followed by oral therapy with warfarin. 5, 6 There are limitations to warfarin therapy, including the need to monitor the international normalized ratio for dose titration and potential for major bleeding complications. 7, 8 Intracranial hemorrhage (ICH) is one of the most devastating potential complications of anticoagulation therapy. 9 ICH accounts for ≈10% of major warfarin-associated hemorrhages and for up to 50% of fatal warfarin-associated bleeding complications. 10 During the past decade, several direct oral anticoagulants (DOACs), including factor IIa (thrombin) and factor Xa inhibitors, have been approved by the Food and Drug Administration. In 2010, based on the results of the RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) Trial, the Food and Drug Administration approved dabigatran, a direct thrombin inhibitor, for prevention of stroke in patients with nonvalvular atrial fibrillation (AF). 11, 12 Since that time, 3 factor Xa inhibitors-rivaroxaban (2011), apixaban (2012), and edoxaban (2015)-have also received Food and Drug Administration approval for prevention of stroke in nonvalvular AF. Several phase 3 clinical trials demonstrated that these agents are at Background and Purpose-Deep vein thrombosis (DVTs) is a common disease with high morbidity if it progresses to pulmonary embolus (PE). Anticoagulation is the treatment of choice; warfarin has long been the standard of care. Early experience with direct oral anticoagulants (DOACs) suggests that these agents may be may be a safer and equally effective alternative in the treatment of DVT/PE. Nontraumatic intracranial hemorrhage (ICH) is one of the most devastating potential complications of anticoagulation therapy. We sought to compare the rates of ICH in patients treated with DOACs versus those treated with warfarin for DVT/PE. Methods-The MarketScan Commercial Claims and Medicare Supplemental databases were used. Adult DVT/PE patients without known atrial fibrillation and with prescriptions for either a DOAC or warfarin were followed for the occurrence of inpatient admission for ICH. Coarsened exact matching was used to balance the treatment cohorts. Cox proportionalhazards regressions and Kaplan-Meier survival curves were used to estimate the association between DOACs and the risk of ICH compared with warfarin.
least equivalent to warfarin for prevention of stroke or systemic embolism in patients with AF. 11, [13] [14] [15] Of note, these trials also demonstrated consistently lower rates of ICH with DOAC therapy compared with warfarin therapy in the AF patient population. 11, [13] [14] [15] [16] Subsequent studies demonstrated noninferiority of DOACs in prevention of recurrent DVT and PE in the VTE patient population. They also showed a more favorable complication profile of DOACs compared with warfarin therapy in this patient population, including a relative decrease in the risk of ICH. [17] [18] [19] [20] [21] [22] [23] [24] There are no postmarketing studies that have reported ICH risk with DOAC therapy in treatment of DVT/ PE. 25, 26 We evaluate the relative risk of nontraumatic ICH in VTE patients treated with DOACs compared with those treated with warfarin, in a large national database.
Methods
Data for this study are commercially available from Truven Health Analytics, and other materials are available from the corresponding author on reasonable request. We extracted insurance claims information from a portion of the MarketScan database, which contains data on millions of patients insured both commercially and through Medicare in the United States from January 2007 to December 2015. 27 Diagnosis information was extracted from inpatient and outpatient records using International Classification of Diseases, Ninth Revision (ICD-9) codes. Outpatient prescriptions were extracted using National Drug Code numbers. MarketScan is a fully deidentified database, therefore this study was exempt from institutional review board approval.
The primary outcome was a primary or secondary inpatient diagnosis (including overnight Emergency Department encounters) of nontraumatic ICH (ICD-9: 430, 431, 432.X), which includes intracerebral, subdural/epidural hemorrhage, subarachnoid hemorrhage, and other ICH. Patients became eligible for inclusion if they had at least 1 period of continuous enrollment for ≥180 day before the date of their first recorded outpatient prescription for a DOAC or warfarin. Prescriptions sufficient for only 1 day of therapy were excluded from index date selection, but otherwise the first prescription date was designated as the index date. Patients with a diagnosis of PE, DVT, or a history of either of these before the index date were included. Patients with a diagnosis of AF, ICH, or an unruptured intracranial aneurysm before the index date (inclusive of the index date in the case of AF) or who were not at least 18 years of age on the index date were excluded. Potential risk factors and other comorbidities were taken from the index period and any prior enrollment periods. The updated Charlson comorbidity index was used. 28 Insurance status was assigned based on the insurance at the index date.
Patients were followed until 1 of 6 end points were reached: (1) the occurrence of the primary outcome (inclusive of the date of first prescription and the date of last follow-up), (2) disenrollment, (3) inpatient death (MarketScan does not record outpatient deaths), (4) discontinuation of anticoagulant therapy for >14 days, (5) switching anticoagulant therapy from DOAC to warfarin or vice versa (but not within the DOAC class), or (6) reaching October 1, 2015 (when International Classification of Diseases, Tenth Revision codes began to be implemented). 29 Initial selection was performed separately for the commercial and Medicare cohorts. Only complete cases were used. The selection process is detailed in Figure I in the online-only Data Supplement.
A Cox proportional-hazards (CPH) model was fit on the unmatched cohort to evaluate the association between the treatment (type of anticoagulant) and the risk of the primary outcome, as well as to produce interpretable effect estimates for selected confounding pretreatment variables. The variance inflation factor was calculated for all independent variables to assess multicollinearity. Interactions between the treatment group and all other independent variables were examined for significance one at a time in the context of the other independent variables. The cohort was then matched using Coarsened Exact Matching to balance confounding variables between those prescribed a DOAC and those prescribed warfarin. 30 Confounding variables were selected to balance the demographics and comorbidities between the cohorts. These included sex, age (continuous), insurance type, Charlson comorbidity score (continuous), hypertension, type II diabetes mellitus, heart failure, vascular disease, pulmonary disease, renal disease, liver disease, obesity, and tobacco use. Balance improvement was assessed with the multivariate L1 statistic and by comparing the standardized mean differences of confounding variables between the unmatched and matched cohorts. Differences between demographic and confounding variables were assessed using t tests or χ 2 tests (weighted versions were used for matched data). Annualized rates were reported as cases per 1000 person-years and were compared using a 2-sided χ 2 test. A second CPH model was fit on the matched cohort, again including confounding variables, to produce a doubly robust estimate for the effect size of the treatment on the primary outcome. 31, 32 Hazard ratios (HRs) for confounding variables were not reported in the matched regression because of the difficulty of interpreting HRs for variables previously balanced by matching. Statistical significance was set at P<0.05. Months were defined as 30-day intervals. Data analyses were conducted in Redivis and R Software. 33, 34 This article was written in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. 35 
Results
A total of 218 620 patients (26 980 DOAC and 191 640 warfarin) were selected with an overall median follow-up of 3.0 months ( Figure I in the online-only Data Supplement). The DOAC cohort had a shorter mean follow-up time compared with the warfarin cohort (3.8 versus 6.2 months; P<0001); It had more patients with ≤1 month of follow-up (31% versus 22%) and fewer patients with >1 year of follow-up (5% versus 12%; P<0.001) compared with the warfarin cohort ( Table 1) . Other demographic differences were accounted for in matching and regression (Table 2) . Among patient encounters with ICH in the DOAC cohort, 75% listed ICD-9 code 431 (intracerebral hemorrhage) as either the primary or secondary diagnosis and 25% listed 432.1 (subdural hemorrhage). In contrast, intracerebral hemorrhage and subdural hemorrhage made up 46% and 36%, respectively, of primary or secondary diagnoses in warfarin cohort ICH patient encounters-ICD-9 codes 430 (subarachnoid hemorrhage) and 432.9 (unspecified ICH) accounted for another 10% each. The DOAC cohort had a mean age of 53 years compared with 56 years in the warfarin cohort (P<0.001) and was composed of 51.5% women compared with 52.2% women in the warfarin cohort (P=0.04). A smaller proportion of the DOAC cohort was enrolled in Medicare compared with the warfarin cohort (12% versus 23%; P<0.001). The DOAC cohort had a higher prevalence of hypertension (56% versus 55%; P=0.002), pulmonary disease (28% versus 26%; P<0.001), liver disease (7% versus 5%; P<0.001), obesity (26% versus 17%; P<0.001), and tobacco use (13% versus 10%; P<0.001) and a lower prevalence of type II diabetes mellitus (22% versus 23%; P=0.05), heart failure (8% versus 10%; P<0.001), vascular disease (16% versus 17%; P<0.001), and renal disease (6% versus 7%; P<0.001).
The incidence rate of ICH was 1.0 cases per 1000 person-years in the DOAC cohort (95% CI, 0.5-1.9) and 3.3 cases per 1000 person-years in the warfarin cohort (95% CI, 3.0-3.7; P<0.0001). The CPH regression fitted before matching revealed several significant associations: treatment with DOAC (HR=0.26; 95% CI, 0. After matching, the multivariate L1 statistic improved from 0.41 to 0.29, and the standardized mean differences of matched variables between treatment groups were reduced to near zero in the matched cohort (from a maximum of 0.291 to a maximum of 0.002), and no significant differences in matched variables remained ( Table 2 ). The DOAC cohort had a lower hazard of ICH compared with warfarin in the matched CPH regression (HR=0.20; 95% CI, 0.09-0.45; P=0.0001; Table 3 ).
Discussion
The recent introduction of DOACs to the collection of anticoagulant medications has changed clinical practice as class 1a evidence has made DOACs the first-line anticoagulant in many patients. This study used a retrospective insurance claims database to evaluate the relative rates of nontraumatic ICH in VTE (DVT/PE) patients without AF, treated with either DOACs or warfarin. Treatment with DOACs is associated with lower rates of ICH compared with warfarin therapy in this VTE patient population.
Previous Clinical Trials
Phase 3 trials in patients with AF have suggested noninferiority or superiority of DOACs in prevention of thromboembolic complications, with more favorable side effect profiles as compared with warfarin (eg, ICH). 11, [13] [14] [15] [36] [37] [38] When ICH does occur, the hemorrhages tends to be smaller, less severe, and less frequently fatal in patients on DOACs compared with patients on warfarin. [39] [40] [41] However, >600 000 patients per year in the United States require prolonged anticoagulation therapy for VTE. [17] [18] [19] With regard to ICH, a pooled analysis of RE-COVER/RE-COVER II revealed 0.1% rate of ICH in dabigatran group versus 0.2% in the warfarin group (P value not reported). 19 RE-MEDY/RE-SONATE did not specifically report on ICH rates; however, dabigatran had a lower rate of major or clinically relevant bleeding complications as compared with warfarin. 18 The EINSTEIN-DVT (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis; 2010) and EINSTEIN-PE (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism; 2012) trials compared rivaroxaban to standard therapy (low-molecular-weight heparin plus warfarin) in acute DVT and PE, respectively, and found that rivaroxaban was noninferior to standard therapy for prevention of recurrent VTE, with lower rates of major and clinically relevant bleeding complications. 20, 21 The rate of ICH in the EINSTEIN-PE trial was 0.1% for the rivaroxaban group versus 0.4% for the warfarin group (P value not reported). ICH rates were not specifically reported in the EINSTEIN-DVT trial. The AMPLIFY trial (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy; 2013) compared apixaban to standard therapy (low-molecular-weight heparin/warfarin) in acute VTE and reported equivalent efficacy of DOACs for prevention of recurrent symptomatic VTE or death related to VTE, as well as lower rates of bleeding complications, including ICH (0.1% with apixaban versus 0.2% with warfarin, P value not reported). 22 Similarly, the Hokusai-VTE (2013) trial reported that edoxaban was noninferior to warfarin for prevention of recurrent VTE, with lower associated ICH (0.1% with edoxaban versus 0.4% with warfarin, P value not reported).
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Results of This Study
In this article, we used a large, commercial database to demonstrate that DOACs are associated with a lower hazard of ICH in DVT/PE patients without AF as compared with warfarin (HR=0.26; P=0.0002). This finding was confirmed in the matched cohort (HR=0.20; P=0.0001), which was the primary study objective. The matching procedure reduced the differences in confounding variables between cohorts to nonsignificant levels. In fact, all standardized mean differences were near zero after matching. Sensitivity analysis with the Medicare cohort recapitulated the direction of the DOAC cohort hazard. It did not achieve significance, but this was likely because of the relatively small proportion of Medicare patients in our cohorts.
The analysis took a doubly robust approach to balance confounding variables between treatment cohorts. Matching confounders between treatment cohorts and then including In addition, it demonstrated that, with or without matching, the treatment hazard is in the same direction and remains statistically significant. Indeed, the treatment hazard became larger after matching. It should be noted that, before matching, the DOAC cohort had slightly more liver disease (6.7% versus 4.7%; P<0.001) and slightly less renal disease (5.9% versus 7.3%; P<0.001) compared with the warfarin cohortboth diseases can result in reduced clearance of anticoagulants. In addition, the DOAC cohort was slightly younger than the warfarin cohort (53 versus 56 years; P<0.001) and thus would be at slightly lower risk of ICH. These differences were accounted for in matching and regression. The findings of this study are consistent with previous studies on DOACs in the VTE patient population. The DOAC cohort had a lower risk of ICH compared with the warfarin cohort in all of our analyses. To our knowledge, this is the first phase 4 (ie, post-marketing, nonclinical trial experience) report of DOAC-associated ICH rates in the literature. Future studies should focus on the long-term complications of DOACs compared with warfarin and should stratify according to the DOAC agent prescribed if sample size allows.
Limitations
Limitations of this study are the same as any retrospective claims database study. The treatment cohorts had a relatively short follow-up time (median, 3.0 months). Previous reports indicate that bleeding complications, including ICH, are clustered at the start of anticoagulation therapy. 10, 42 Nonetheless, the short follow-up period in the present cohort must be considered when interpreting the results of this report. The majority of the cohort were commercially insured patients, who may go in and out of insurance coverage, resulting in premature termination of database-captured follow-up. In addition, the index period for which risk factors and other variables were collected extended only to 2007 at most. Thus, it is possible that patients diagnosed with AF before 2007 were included in the study despite the intended exclusion of patients with AF from the cohort.
The way in which inclusion criteria and outcomes were coded is vulnerable to bias. Patients with a diagnosis of DVT/ PE in their index period were assumed to be prescribed anticoagulants for that diagnosis, which is not necessarily true. For ICH, only primary and secondary inpatient diagnoses were considered, so patients with a tertiary or lower diagnosis of ICH were not captured. Some events may have been missed if a patient was diagnosed in the Emergency Department but not admitted. It was not possible to determine the pathogenesis or severity of the ICH events outside of details contained in ICD-9 codes. A systematic review has shown that at least half of administrative databases have a positive predictive value of 89% for ICH (ICD-9 431) and 93% for subarachnoid hemorrhage. 43 The overall negative predictive value for cerebrovascular disease in general was at least 95%. MarketScan specifically has been validated for the identification of postoperative complications in spinal surgery, for which it achieved results similar to prospective studies. 44 MarketScan does not capture over-the-counter medications, so the contribution of aspirin and dual antiplatelet therapy could not be assessed. The proportion of warfarin patients with poor therapeutic range control is unknown, which may be an additional factor in the relative benefits of DOACs compared with warfarin. Finally, almost all patients in the DOAC cohort were initially prescribed rivaroxaban-possibly because of its earlier Food and Drug Administration approval for recurrent VTE compared with other DOACs and its convenient once daily dosing-which limits the generalizability of our results to all DOACs.
Conclusions
This report provides evidence that treatment with DOACs is associated with lower rates of nontraumatic ICH compared with warfarin therapy in the VTE patient population. This result requires further validation in prospective postmarketing studies that can better capture relevant confounding factors outside of the clinical trial setting.
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